Clinical Trial Update: Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy [EARLY_Phase 1]

View source ↗

Summary

Clinical trial update on EXG001-307 for Spinal Muscular Atrophy, an early-phase 1 study evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• EXG001-307

Snippet

Sponsor: Guangzhou Jiayin Biotech Ltd | Conditions: Spinal Muscular Atrophy (SMA) | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION